CAS: 159752-10-0; (R)-2-Amino-N-(3-(Benzyloxy)-1-(1-(Methylsulfonyl)Spiro[indoline-3,4'-Piperidin]-1'-yl)-1-Oxopropan-2-yl)-2-Methylpropanamide Methanesulfonate

该化合物是一个非pptide生长激素秘库,模仿grelin的动作,激素刺激食欲和生长激素释放的激素,主要以其可能增加生长激素水平,提高肌肉质量和体力,使其在医疗和运动环境中都引起兴趣而闻名.MK 0677功能与生长激素秘密受体(GHS-R)结合,导致从垂体腺中分离出生长激素,该化合物经常被研究其潜在的治疗用途,例如生长激素缺乏,缓冲和与年龄有关的肌肉损失.此外,MK 0677因其对身体构成,新陈代谢和食欲调节的影响而受到调查.然而,它在体育和身体建设中的使用引起了伦理问题,并且受到许多体育组织的禁止.与影响荷尔蒙途径的任何物质一样,必须仔细研究其安全特征,潜在副作用和长期影响.

结构式图片

上下游产品

isonipecotic acid N-B°C-D-serine(Bzl)-OH benzyl bromide 1-benzyloxycarbonylpiperidine-4-carboxylic acid

合成工艺路线路线简述

    螺[吲哚啉-3,4'-哌啶]-1'-羧酸苄酯置于palladium On Activated Charcoal 甲烷磺酸,氢气,1-羟基苯并三唑,N,N-二异丙基乙胺,N,N'-二环己基碳二亚胺体系中,用 四氢呋喃,乙醇,水,乙酸乙酯 用作溶剂,5.0~65.0 °C,275.79 Kpa 条件下,反应 21.5H,反应生成伊布莫仑甲磺酸盐
    参考文献:合成基于口服螺螺吲哚的生长激素促分泌素mk-677
    标题:合成基于口服螺螺吲哚的生长激素促分泌素mk-677
    摘要:默克生长激素促分泌素的制备;描述了mk-677.费歇尔吲哚/还原为基础的策略提供了这种有效化合物的新型螺二氢吲哚核.该优化的序列仅需要分离一种中间体10并从异二十二烯酸3提供48%的总收率的mk-677 .
    Doi:10.1016/s0040-4020(97)00359-1

    海关参考信息

    专利信息


    专利号:US-9751877-B2
    优先权日:2012-09-21
    标题 :Substituted pyrido[1,2-a]pyrazines for the treatment of neurodegenerative and neurological disorders
    发明人:PETTERSSON MARTIN YOUNGJIN; JOHNSON DOUGLAS SCOTT; SUBRAMANYAM CHAKRAPANI; O'DONNELL CHRISTOPHER JOHN; AM ENDE CHRISTOPHER WILLIAM; GREEN MICHAEL ERIC; PATEL NANDINI CHATURBHAI; STIFF CORY MICHAEL; TRAN TUAN PHONG; KAUFFMAN GREGORY WAYNE; STEPAN ANTONIA FRIEDERIKE; VERHOEST PATRICK ROBERT
    权利人:PFIZER
    摘要:Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I n nas defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

    专利号:US-9771379-B2
    优先权日:2015-09-24
    标题:N-(2-(2-amino-6-substituted-4,4a,5,6-tetrahydropyrano[3,4-d][1,3]OXAZIN-8a(8H)-yl)-thiazol-4-yl) amides
    发明人:BRODNEY MICHAEL AARON; BUTLER CHRISTOPHER RYAN; ZHANG LEI; O'NEILL BRIAN THOMAS
    权利人:PFIZER
    摘要:The present invention is directed to compounds, tautomers and pharmaceutically acceptable salts of the compounds which are disclosed, wherein the compounds have the structure of Formula I, n nwherein the variables R 1 , R 2 , R 3 , R 4 and X are as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

    专利号:WO-2012172449-A1
    优先权日:2011-06-13
    标题:Lactams as beta secretase inhibitors
    发明人:BRODNEY MICHAEL AARON
    权利人:PFIZER; BRODNEY MICHAEL AARON
    摘要:Compound and pharmaceutically acceptable salts of the compound are disclosed, wherein the compound has the structure (I) as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed. The compound of formula I is useful as beta secretase inhibitor for use in the treatment of Alzheimer's and other neurodegenerative and/or neurological disorders.

    专利号:US-2016229847-A1
    优先权日:2013-10-04
    标 题:Novel bicyclic pyridinones as gamma-secretase modulators
    发明人:PETTERSSON MARTIN YOUNGJIN; AM ENDE CHRISTOPHER WILLIAM; GREEN MICHAEL ERIC; JOHNSON DOUGLAS SCOTT; KAUFFMAN GREGORY WAYNE; O'DONNELL CHRISTOPHER WILLIAM; PATEL NANDINI CHATURBHAI; STEPAN ANTONIA FRIEDERIKE; STIFF CORY MICHAEL; SUBRAMANYAM CHAKRAPANI; TRAN TUAN PHONG; VERHOEST PATRICK ROBERT
    权利人:PFIZER
    摘要:Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula II as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

    专利号:US-9067934-B2
    优先权日:2011-03-31
    标题 :Bicyclic pyridinones
    发明人:PETTERSSON MARTIN YOUNGJIN; JOHNSON DOUGLAS SCOTT; SUBRAMANYAM CHAKRAPANI; O'DONNELL CHRISTOPHER JOHN; AM ENDE CHRISTOPHER WILLIAM; FISH BENJAMIN ADAM; GREEN MICHAEL ERIC; MULLINS PATRICK BRADLEY; STIFF CORY MICHAEL; TRAN TUAN PHONG; NAVARATNAM THAYALAN
    权利人:PFIZER
    摘要:Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I n nas defined herein. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

    专利号:US-8962616-B2
    优先权日:2012-05-04
    标 题:Heterocyclic substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
    发明人:BRODNEY MICHAEL AARON; BUTLER CHRISTOPHER RYAN; BECK ELIZABETH MARY; DAVOREN JENNIFER ELIZABETH; O'NEILL BRIAN THOMAS
    权利人:PFIZER
    摘要:Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I, n nas defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.
    杭州言鼎生物医药科技有限公司
    ⚠️ 未注册 · 未认证企业
    ⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
    数据来源于公开网络搜索,平台未作核实,请自行辨别。
    🏢敬请 企业认领
    🏬开设公司展台
    📢获取免费会员权益
    🎖️点亮专属注册企业标签
    📇展现公司完整信息 样本查看立即注册认领 →
    网址: http://www.yandingbio.com
    企业联系电话:86-18989469219👤
    📞杭州言鼎生物医药科技有限公司 ⚠️参考联系方式
    联系人:蔡先生
    电话:86-18989469219
    手机:18989469219

    邮箱:sales@yandingbio.com
    通信地址: 杭州钱塘新区下沙金隅金座1-813
    邮编: 310018
    🆔 联系时候可告知是从"百琢研"平台获取的信息.
    ⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

    地址:杭州钱塘新区下沙金隅金座1-813
    ⚠️ 未注册 · 未认证企业
    注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别
    ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
    第 1 / 1 页

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    主要参考文献


    1: Adunsky A, Chandler J, Heyden N, Lutkiewicz J, Scott BB, Berd Y, Liu N, Papanicolaou DA. MK-0677 (ibutamoren mesylate) for the treatment of patients recovering from hip fracture: a multicenter, randomized, placebo-controlled phase IIb study. Arch Gerontol Geriatr. 2011 Sep-Oct;53(2):183-9. doi: 10.1016/j.archger.2010.10.004. Epub 2010 Nov 9. The effects of MK-0677, an oral growth hormone secretagogue, in patients with hip fracture. J Am Geriatr Soc. 2004 Apr;52(4):516-23.

    合成参考文献


    参考文献:10.1359/jbmr.1999.14.7.1182
    摘要:Murphy MG, Bach MA, Plotkin D, Bolognese J, Ng J, Krupa D, Cerchio K, Gertz BJ. Oral administration of the growth hormone secretagogue MK-677 increases markers of bone turnover in healthy and functionally impaired elderly adults. The MK-677 Study Group. J Bone Miner Res. 1999 Jul;14(7):1182–8. doi: 10.1359/jbmr.1999.14.7.1182.
    参考文献:10.2174/187153008784534367
    摘要:Gómez JM. Growth hormone and insulin-like growth factor-I as an endocrine axis in Alzheimer's disease. Endocr Metab Immune Disord Drug Targets. 2008 Jun;8(2):143–51. doi: 10.2174/187153008784534367.
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知